Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

One calcitriol dose transiently increases Helios(+)FoxP3(+) T cells and ameliorates autoimmune demyelinating disease.
Alemtuzumab and multiple sclerosis: therapeutic application.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Spin-offs: Meet the structure specialists
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Oxidative modification of serum proteins in multiple sclerosis.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
B cells and multiple sclerosis.
Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica.

Pages